Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real‐world outcomes from a population‐based cohort

Autor: Ryan J. Stubbins, Maria Stamenkovic, Claudie Roy, Judith Rodrigo, Shanee Chung, Florian C. Kuchenbauer, Kevin A. Hay, Jennifer White, Yasser Abou Mourad, Maryse M. Power, Sujaatha Narayanan, Donna L. Forrest, Cynthia L. Toze, Heather J. Sutherland, Stephen H. Nantel, Thomas J. Nevill, Aly Karsan, Kevin W. Song, David S. Sanford
Rok vydání: 2022
Předmět:
Zdroj: European Journal of Haematology. 108:437-445
ISSN: 1600-0609
0902-4441
Popis: Acute myeloid leukaemia (AML) is a disease of older adults, who are vulnerable to socio-economic factors. We determined AML incidence in older adults and the impact of socio-economic factors on outcomes.We included 3024 AML patients (1996-2016) identified from a population-based registry.AML incidence in patients ≥60 years increased from 11.01 (2001-2005) to 12.76 (2011-2016) per 100 000 population. Among 879 patients ≥60 years in recent eras (2010-2016), rural residents (100 000 population) were less likely to be assessed by a leukaemia specialist (39% rural, 47% urban, p = .032); no difference was seen for lower (43%, quintile 1-3) vs. higher (47%, quintile 4-5) incomes (p = .235). Similar numbers received induction chemotherapy between residence (16% rural, 18% urban, p = .578) and incomes (17% lower, 17% high, p = 1.0). Differences between incomes were seen for hypomethylating agent treatment (14% low, 20% high, p = .041); this was not seen for residence (13% rural, 18% urban, p = .092). Among non-adverse karyotype patients ≥70 years, 2-year overall survival was worse for rural (5% rural, 12% urban, p = .006) and lower income (6% low, 15% high, p = .017) patients.AML incidence in older adults is increasing, and outcomes are worse for older rural and low-income residents; these patients face treatment barriers.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje